[{"address1": "7800 Susquehanna St.", "address2": "Suite 505", "city": "Pittsburgh", "state": "PA", "zip": "15208", "country": "United States", "phone": "412-901-0315", "website": "https://www.lipella.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.", "fullTimeEmployees": 5, "maxAge": 86400, "priceHint": 4, "previousClose": 0.664, "open": 0.653, "dayLow": 0.57, "dayHigh": 0.6548, "regularMarketPreviousClose": 0.664, "regularMarketOpen": 0.653, "regularMarketDayLow": 0.57, "regularMarketDayHigh": 0.6548, "volume": 39626, "regularMarketVolume": 39626, "averageVolume": 26314, "averageVolume10days": 11540, "averageDailyVolume10Day": 11540, "marketCap": 4335214, "fiftyTwoWeekLow": 0.57, "fiftyTwoWeekHigh": 2.71, "priceToSalesTrailing12Months": 9.079952, "fiftyDayAverage": 0.69658, "twoHundredDayAverage": 1.024535, "currency": "USD", "enterpriseValue": 2345615, "floatShares": 4800069, "sharesOutstanding": 7605640, "sharesShort": 29427, "sharesShortPriorMonth": 45658, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.40566003, "heldPercentInstitutions": 0.04994, "shortRatio": 1.86, "shortPercentOfFloat": 0.0047999998, "impliedSharesOutstanding": 7605640, "bookValue": 0.364, "priceToBook": 1.5659341, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -4742949, "trailingEps": -0.74, "enterpriseToRevenue": 4.913, "52WeekChange": -0.72397095, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "LIPO", "underlyingSymbol": "LIPO", "shortName": "Lipella Pharmaceuticals Inc.", "longName": "Lipella Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1671460200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d39a1b66-6fea-3b6c-8773-cda09b9e9d93", "messageBoardId": "finmb_35907207", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.57, "targetHighPrice": 2.0, "targetLowPrice": 2.0, "targetMeanPrice": 2.0, "targetMedianPrice": 2.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 2105299, "totalCashPerShare": 0.277, "totalDebt": 115702, "quickRatio": 3.94, "currentRatio": 5.456, "totalRevenue": 477449, "debtToEquity": 4.517, "revenuePerShare": 0.075, "returnOnAssets": -0.78676003, "returnOnEquity": -1.4873599, "freeCashflow": -1783641, "operatingCashflow": -3460621, "revenueGrowth": 0.236, "operatingMargins": -8.3469, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]